Search

Chromous sulfate

Defactinib

[L53208,A273943] Defactinib was approved by the US FDA in May 2025 in a co-package alongside [avutometinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian

ISS-1018

(TNF-alpha) by plasmacytoid dendritic cells (pDC). … ISS 1018 signals through Toll-like receptor 9 (TLR9) to induce the production of immunoglobulin by B cells and interferon (IFN) -alpha, IFN-beta, interleukin-12 (IL-12), and tumor necrosis factor - alpha

Queuine

Quantities of queuine have been found in tomatoes, wheat, coconut water, and milk from humans, cows, and goats. Humans salvage and recover queuine from either ingested food or the gut flora. … All eukaryotic organisms, including humans, transform queuine to queuosine by placing it in the wobble position (anticodon) of several tRNAs including aspartic acid, asparagine, histidine, and tyrosine

AG-702

HSPs are present in all cells in all life forms from bacteria to mammals, and their structure and function are similar across these diverse life forms. … This drug is developed by antigenics for the treatment of genital herpes infection and is under phase I of clinical trial.

Clotiazepam

Clotiazepam is a thienodiazepine, not approved for sale in the U.S. or Canada, but has been approved in the U.K. It is a schedule IV drug in Canada.

NV-52

NV-52 is an investigational synthetic flavonoid thromboxane synthase (TXS) inhibitor developed for the maintenance of remission in inflammatory bowel disease.

Bupropion

Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the uptake of the neurotransmitters norepinephrine and dopamine from the synaptic cleft, therefore prolonging their … [A178804,A178807] When used as an aid to smoking cessation, bupropion is thought to confer its anti-craving and anti-withdrawal effects by inhibiting dopamine reuptake, which is thought to be involved

Aripiprazole lauroxil

Aripiprazole lauroxil was initially approved by the FDA in October 2015 under the market name Aristada for the treatment of schizophrenia. … pathway activating D2 receptors, whereas negative symptoms may result from a decreased activity in the mesocortical dopaminergic pathway with D1 receptors predominating [T28].

Indium In-111 imciromab pentetate

Indium In-111 imciromab pentetate is a mouse monoclonal antibody labelled with the radioisotope Indium-111 which was used for cardiac imaging under the trade name Myoscint, but was withdrawn in 1993.